MXPA04007192A - Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i. - Google Patents

Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i.

Info

Publication number
MXPA04007192A
MXPA04007192A MXPA04007192A MXPA04007192A MXPA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A
Authority
MX
Mexico
Prior art keywords
melagatran
pharmaceutically acceptable
cells
acceptable derivative
treatment
Prior art date
Application number
MXPA04007192A
Other languages
English (en)
Spanish (es)
Inventor
Nilsson Bo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04007192A publication Critical patent/MXPA04007192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA04007192A 2002-01-23 2003-01-21 Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i. MXPA04007192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
MXPA04007192A true MXPA04007192A (es) 2004-10-29

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007192A MXPA04007192A (es) 2002-01-23 2003-01-21 Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i.

Country Status (14)

Country Link
US (2) US7045502B2 (cg-RX-API-DMAC7.html)
EP (1) EP1469874A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516035A (cg-RX-API-DMAC7.html)
KR (1) KR20040075096A (cg-RX-API-DMAC7.html)
CN (1) CN100430089C (cg-RX-API-DMAC7.html)
BR (1) BR0306798A (cg-RX-API-DMAC7.html)
CA (1) CA2472241A1 (cg-RX-API-DMAC7.html)
IL (1) IL162853A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007192A (cg-RX-API-DMAC7.html)
NO (1) NO20043483L (cg-RX-API-DMAC7.html)
NZ (1) NZ533749A (cg-RX-API-DMAC7.html)
SE (1) SE0200198D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003061682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405342B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
CN121843705A (zh) 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CN1729010A (zh) 2006-02-01
US20060148720A1 (en) 2006-07-06
KR20040075096A (ko) 2004-08-26
NO20043483L (no) 2004-08-20
US20050090424A1 (en) 2005-04-28
BR0306798A (pt) 2004-12-07
CA2472241A1 (en) 2003-07-31
JP2005516035A (ja) 2005-06-02
WO2003061682A1 (en) 2003-07-31
EP1469874A1 (en) 2004-10-27
SE0200198D0 (sv) 2002-01-23
US7045502B2 (en) 2006-05-16
CN100430089C (zh) 2008-11-05
IL162853A0 (en) 2005-11-20
ZA200405342B (en) 2005-09-28
NZ533749A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
Naziruddin et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation
Nijhoff et al. Glycemic stability through islet‐after‐kidney transplantation using an alemtuzumab‐based induction regimen and long‐term triple‐maintenance immunosuppression
US7045502B2 (en) Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus
CN109640959A (zh) 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
KR100828807B1 (ko) 새로운 용도의 덱스트란 설페이트
Yue et al. Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation
Vasanthan et al. Periodontal treatment considerations for cell transplant and organ transplant patients.
JP2021516052A (ja) 胸腺組織に由来する制御性t細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用
RU2450052C2 (ru) Способ получения бета-клеток поджелудочных желез кроликов и композиция для стимуляции выработки собственного инсулина у пациента
Kenmochi et al. Protection of mouse islet isografts from nonspecific inflammatory damage by recipient treatment with nicotinamide and 15-deoxyspergualin
CN102665703B (zh) 在胰岛移植中作为佐剂的cxcr1/2抑制剂
US20040214803A1 (en) Use of vitamin d3 analogue for the treatment of autoimmune diabetes
US8048411B2 (en) Co-transplantation of hepatic stellate cells and islet cells
WO2017209270A1 (ja) 25-ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたt細胞及び/又はb細胞に選択的な細胞死誘導剤又は細胞死促進剤
CN114762697B (zh) 用于治疗糖尿病的药物及方法
RU2315621C2 (ru) Применение ингибитора или антагониста тканевого фактора
AU2003202192A1 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
CN114762725B (zh) 一种治疗糖尿病的方法
Yoshimatsu et al. The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation
RU2758536C1 (ru) Способ снижения воспалительной гиперактивации нейтрофилов
Berney et al. Islet Allotransplantation
Mattke Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation
Mineo et al. Islet and pancreas transplantation
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
McCall Enhancing engraftment of islets of Langerhans and other cellular therapies for diabetes